DWM
REGN icon

Doyle Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Doyle Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$63K – 622
2019
Q2 		$63K Buy
+200
New +$66.6K 0.01% 323
2019
Q1 		– Sell
-175
Closed -$65K – 608
2018
Q4 		$65K Buy
+175
New +$64.1K 0.01% 311

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Doyle Wealth Management's REGN Position: Q3 2019 in Review

Doyle Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 200 shares — an estimated $63K sold.

Doyle Wealth Management first reported a position in REGN in Q4 2018 and held it in 2 quarters. The position peaked at $65K in Q4 2018. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

  • Doyle Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 200 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $63K.
  • Doyle Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Doyle Wealth Management's Regeneron Pharmaceuticals position peaked at $65K in Q4 2018.
  • 632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.